CD274 and neoplasm: This includes the targeting with radiolabeled antibodies, antibody fragments, or small proteins of checkpoints (i.e., CTLA-4, PD-1, PD-L1) [102,103,104,105,106], tumor infiltrating lymphocytes (ex.